Tesamorelin is a synthetic version of growth hormone-releasing hormone (GHRH), the signal your brain sends to the pituitary to release growth hormone. What sets it apart from other peptides in this family is the research behind it: tesamorelin is FDA-approved, under the brand name Egrifta, for reducing excess abdominal fat in people with HIV-associated lipodystrophy, and it did so in large trials by targeting visceral fat specifically, the deep fat around the organs that drives metabolic risk.
Dr. Loera prescribes tesamorelin off-label for adults with stubborn abdominal fat, slowing metabolism and declining growth hormone in midlife, usually as part of a body recomposition plan with training and nutrition targets attached. Because it works through your own pituitary, growth hormone is released in natural pulses with the body’s feedback loops intact.
